Foster City, CA, United States
Foster City, CA, United States

Time filter

Source Type

Patent
Gilead Sciences Inc. | Date: 2016-09-13

Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of TLR8 and pharmaceutically acceptable salts thereof, useful in treating HIV infections.


Patent
Gilead Sciences Inc. | Date: 2016-09-16

Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1 position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.


Patent
Gilead Sciences Inc. | Date: 2016-10-20

The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R^(1), R^(2), R^(3), and R^(4 )are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk. In certain embodiments, also disclosed are methods for treating a cancer in a subject (e.g., a human) in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof.


Patent
Gilead Sciences Inc. | Date: 2016-08-23

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.


Patent
Gilead Sciences Inc. and Janssen Science Ireland Uc | Date: 2016-06-28

The invention provides a solid oral dosage form comprising rilpivirine or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.


Patent
Gilead Sciences Inc. | Date: 2017-04-05

The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament. The compounds take the form (I).


Patent
Gilead Sciences Inc. | Date: 2017-04-05

Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo(1,2-f] [1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 2 position of the nucleoside sugar is substituted with halogen and carbon substitutents. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections caused by both wild type and mutant strains of HCV.


Patent
Gilead Sciences Inc. | Date: 2017-04-05

The present application provides for a compound of Formula IV,


Patent
Gilead Sciences Inc. | Date: 2017-01-04

The present application provides for a compound of Formula I,


The present invention relates to compounds of Formula (I):

Loading Gilead Sciences Inc. collaborators
Loading Gilead Sciences Inc. collaborators